CAS: 475110-96-4; 4,4'-(6-(2-(Difluoromethyl)-1H-Benzo[d]Imidazol-1-yl)-1,3,5-Triazine-2,4-Diyl)Dimorpholine

上下游产品

morpholine 4-(4-chloro-6-(2-(difluoromethyl)-1H-benzo[d]imidazole -1-yl)-1,3,5-triazin-2-yl)morpholine 2-chloro-4,6-di-morpholin-4-yl-[1,3,5]triazine 2-(difluoromethyl)-1H-benzo[d]imidazole

4-(4-氯-6-(2-(二氟甲基)-1H-苯并[d]咪唑-1-基)-1,3,5-三嗪-2-基)吗啉 以87的收率获得产物2-(2-二氟甲基苯并咪唑-1-基)-4,6-二吗啉基-1,3,5-三嗪
参考文献:Heterocyclic Compound And Antitumor Agent Containing The Same As Effective Ingredient
标题:Heterocyclic Compound And Antitumor Agent Containing The Same As Effective Ingredient
摘要:本发明涉及由式i表示的杂环化合物或其药学上可接受的盐,以及含有该杂环化合物作为有效成分的抗肿瘤剂: 其中x代表氮原子或ch;r1代表chnf3-N(其中n为1或2),羟基c1-C6烷基,Nhr6(其中r6代表氢原子或cor(其中r代表氢原子,C1-C6烷基或c1-C6烷氧基));r2代表吗啡环(可以被取代为一到四个c1-C6烷基),硫代吗啡环,哌啶环,吡咯烷基(可以被羟基c1-C6烷基取代),噁唑烷基(可以被一到两个c1-C6烷基取代)或四氢-1,4-噻唑-1-氧-4-基;r3和r4各自代表氢原子或c1-C6烷基;r5代表氢原子,氨基或羟基.

专利信息

专利号:US-12391691-B2
优先权日:2018-11-16
标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
发明人：PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
权利人:AMGEN INC
摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as

专利号:US-2025206736-A1
优先权日:2019-11-14
标题 :Synthesis of kras g12c inhibitor compound
发明人：CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
权利人:AMGEN INC
摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

专利号:US-2025206743-A1
优先权日:2022-03-25
标 题:Tyk2 inhibitor synthesis and intermediates thereof
发明人：MASSE CRAIG E; PHADKE AVINASH S; LAWSON JON P; LEVY STUART; YANG XIAOWEI; WU GUISHENG; FAN SHUFENG
权利人:TAKEDA PHARMACEUTICALS CO
摘要:Described herein are methods of synthesis of a tyrosine-protein kinase 2 (TYK2) inhibitor and to intermediate compounds of the synthesis and methods of making the intermediates. Also provided are pharmaceutically acceptable compositions including compounds prepared by the synthetic method and methods of treating disorders using the same.

专利号:US-2025289827-A1
优先权日:2022-12-02
标 题:Morphic forms of a mutant braf degrader and methods of manufacture thereof
发明人：YU ROBERT T; HE MINSHENG; SCHNADERBECK MATTHEW J; KREGER BRIDGET; POLLOCK ROY MACFARLANE; JIANG SIYI; LI MEIQI; CHEN BOLU; LU JIANNAN
权利人:C4 THERAPEUTICS INC
摘要:Advantageous isolated morphic forms of (3R)-3-[6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluorophenoxy]-4-oxoquinazolin-3-yl]-8-[2-[1-[3-(2,4-dioxo-1,3-diazinan-1-yl)-5-fluoro-1-methylindazol-6-yl]-4-hydroxypiperidin-4-yl]acetyl]-1-oxa-8-azaspiro[4.5]decane (Compound 1), which is a mutant BRAF degrader, and methods to prepare Compound 1 morphic forms for therapeutic applications are provided in the invention. The invention also provides improved methods for the synthesis of Compound 1, new pharmaceutical compositions comprising Compound 1, and new uses of Compound 1.

专利号:US-2023192681-A1
优先权日:2019-11-14
标 题 :Improved synthesis of kras g12c inhibitor compound

专利号:US-2009227575-A1
优先权日:2008-03-04
标 题 :7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS
发明人：VENKATESAN ARANAPAKAM MUDUMBAI; CHEN ZECHENG; DOS SANTOS OSVALDO; BROOIJMANS NATASJA; GOPALSAMY ARIAMALA
权利人:WYETH CORP
摘要:A 7H-pyrrolo[2,3-h]quinazoline compound of the formula I n n n n n n n n n n wherein Ar, R 1 , R 2 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , and n are as defined in the specification, and methods for making same.